Gene · 6709
SPTAN1: spectrin alpha, non-erythrocytic 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SPTAN1: spectrin alpha, non-erythrocytic 1. Genes, record 6709. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6709
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q13813 | Spectrin alpha chain, non-erythrocytic 1 | 2,472 | 7 | Ensembl, GeneID, HGNC |
Source UniProt
Patents25
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 65098 | Q13813 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 9160 | Q13813 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 9410 | Q13813 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 9410 | Q13813 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 9160 | Q13813 | Espacenet |
| JP 2023064789 A | 2023-05-12 | 88 | Q13813 | Espacenet |
| WO 2023074712 A | 2023-05-04 | 34 | Q13813 | Espacenet |
| JP 2022141755 A | 2022-09-29 | 736 | Q13813 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 82904 | Q13813 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 185875 | Q13813 | Espacenet |
1 to 10 of 25
See all 25 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,199
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SPTAN1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 4 | 2025 |
| U54GM104938 | Oklahoma Shared Clinical and Translational Resources | 4 | 2025 |
| R01NS094003 | Axonal Pathology and TBI-Related Neurodegeneration (TReND) | 3 | 2025 |
| IK2RX003651 | Traumatic and Treatable Vascular Pathology in the Outcome of TBI | 2 | 2025 |
| P30CA013330 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 2 | 2025 |
| P30CA022453 | CANCER CENTER SUPPORT GRANT | 2 | 2025 |
| P30CA054174 | Mays Cancer Center at UT Health SA | 2 | 2025 |
1 to 10 of 1,199Source NIH's project files
See all 1,199 nih grantsPapers1,635
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Functional Characterization of RNA Profiles in Processing Bodies of Embryonic Stem Cells and Mesodermal Cells. | Genomics Proteomics Bioinformatics | 2026 | 42671352 | PubTator, text mining | PubMed |
| Antisense oligonucleotides treatment uncovers differences in the modulation of dysregulated intracellular pathways in Spinal Muscular Atrophy motoneurons. | Cell Death Dis | 2026 | 42443163 | PubTator, text mining | PubMed |
| Elucidating the Role of SET as a Key Contributor to Neurodevelopmental Disability Within the 9q34.11 Deletion Syndrome Interval. | Clin Genet | 2026 | 42432431 | PubTator, text mining | PubMed |
A Dose-Response Study on Human FGF21 to Inhibit Necrosis, Spectrin Breakdown, and to Increase Intracellular Cold Shock Proteins in Cultured Cortical Neurons Subjected to Oxygen-Glucose Deprivation Injury. | Mol Neurobiol | 2026 | 42387004 | PubTator, text mining | PubMed |
| Role of Spatial Heterogeneity in Muscle-Invasive Bladder Cancer on Overall Survival and Immunotherapy Response. | Cancers (Basel) | 2026 | 41827808 | PubTator, text mining | PubMed |
| Non-Conventional and Emerging Autoantibodies in Sjögren's Disease. | J Inflamm Res | 2026 | 41798638 | PubTator, text mining | PubMed |
| Targeting Expanded CUG and CTG Repeats as a Therapeutic Approach for Myotonic Dystrophy Type 1 (DM1). | ChemMedChem | 2026 | 41797662 | PubTator, text mining | PubMed |
| Neurodegeneration Biomarkers in Epilepsy: A Critical Review of Current Findings. | Life (Basel) | 2026 | 41752932 | PubTator, text mining | PubMed |
| Molecular Profiling of Polish Pediatric Patients with Epilepsy: A Single-Center Diagnostic Experience Using Next-Generation Sequencing. | Genes (Basel) | 2026 | 41751517 | PubTator, text mining | PubMed |
| Deciphering the Impact of RAC1-SPTAN1 in ARPKD Cystogenesis Using Multifaceted Models. | Adv Sci (Weinh) | 2026 | 41742835 | PubTator, text mining | PubMed |
1 to 10 of 1,635
See all 1,635 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6709
GET https://conductscience.org/api/genes/v1/6709/patents?page=2